GeoVax Labs, Inc. — Q1 2013 Form 10-Q
Reporting period: Three months ended March 31, 2013. GeoVax is a development-stage biotechnology company developing HIV vaccines; it had no approved products or product sales. Revenue consisted of NIH grant funding recognized as related costs were incurred.
Financial results and liquidity
| Metric | Q1 2013 | Q1 2012 / comparison |
|---|---|---|
| Grant revenue | $797,040 | $854,063 |
| Research and development expense | $881,988 | $1,072,354 |
| General and administrative expense | $612,943 | $512,818 |
| Total operating expenses | $1,494,931 | $1,585,172 |
| Net loss | $696,797 | $730,513 |
| Loss per share | $0.03 | $0.04 |
| Net cash used in operations | $344,489 | $1,236,686 |
At March 31, cash and cash equivalents were $1,751,436, up from $1,035,925 at December 31, 2012. Working capital was $1,664,017, compared with $1,017,439. Total assets were $2,129,745 and current liabilities were $349,782. The filing reports no long-term debt or committed credit lines. Operating margin and conventional profitability measures are not meaningful given grant-funded operations and continuing losses.
Changes and notable items
- Revenue declined about 7% year over year, reflecting lower grant-related expenditures. R&D expense fell about 18%, while reported G&A expense rose about 20%; excluding stock-based compensation, G&A declined from $451,974 to $359,181.
- Net loss narrowed about 5%. Operating cash use also decreased; the year-over-year difference reflects losses, noncash charges, and working-capital movements.
- Financing provided $1.06 million in Q1 2013, versus $2.31 million in Q1 2012. The 2013 proceeds came from exercise of 1,766,667 Series B warrants after their exercise price was reduced from $0.75 to $0.60.
- The warrant repricing and extension generated a $218,551 G&A charge, contributing to total stock-based compensation of $265,825, versus $81,576 a year earlier. At quarter-end, 9,458,892 warrants were outstanding.
- Purchase commitments were approximately $186,000, expected to be due in 2013. Lease payments were $94,040 for the remainder of 2013 and $128,920 in 2014.
Outlook, risks, and contingencies
Management expected available cash and remaining NIH grant funds to support planned operations into the first quarter of 2014 and anticipated raising additional capital during 2013, with no assurance financing would be available on acceptable terms or at all. The company reported about $1.3 million remaining under its $20.4 million IPCAVD grant and about $900,000 remaining under a separate $1.9 million clade C grant as of March 31, 2013. The latter grant period ends in August 2013.
Management anticipated another NIH-funded Phase 1 therapeutic trial starting in mid-2013 and discussed a preventive-vaccine Phase 2 efficacy trial expected to begin in 2014. Funding and timing were uncertain. The company expected continued losses and higher R&D costs as trials advance; failure to raise funds could require it to scale back or terminate operations, or seek a merger or acquisition. Vaccine effectiveness, safety, clinical-trial outcomes, regulatory approval, and future grant support remain significant risks. No material changes to previously disclosed risk factors were reported. No legal proceedings were reported.
Important facts for investors to verify
- Funding runway depends on remaining grant availability and additional financing; confirm current cash burn, grant timing, and financing plans.
- Verify clinical-trial progress, NIH/HVTN support, and the status and funding of the anticipated trials.
- The filing lists 20,499,944 common shares outstanding at March 31, while its cover reports 20,449,944 as of May 1, 2013; confirm the post-quarter share count and explain the difference.
- Assess potential dilution: the filing reports 9,458,892 warrants outstanding and 1,050,667 common shares reserved for conversion of preferred stock.